🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Abbott India Limited ABBOTINDIA NIFTY_MIDNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.abbott.co.in

Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, neuro-psychiat, pain management, respiratory, hepatic, neuroscience, metabolics, gennext, and consumer care products. The company was formerly known as Knoll Pharmaceuticals Limited and changed its name to Abbott India Limited in July 2002. The company was founded in 1910 and is headquartered in Mumbai, India. Abbott India Limited operates as a subsidiary of Abbott Capital India Limited.

READ MORE ›
₹26,855.00
-10.28% 1Y

Market & Price

Market Cap
₹57,065.00 Cr
Current Price
₹26,855.00
High / Low (52W)
₹35,195.00 / ₹25,180.00
Beta
-0.01

Valuation

Stock P/E
36.76
Industry PE
37.60
Forward P/E
29.55
PEG Ratio
-
Book Value
₹2,246.68
Price to Book
11.95
P/S
8.24
EV/EBITDA
28.99
Dividend Yield
1.95%

Profitability & Returns

ROCE
41.87%
ROE
34.46%
ROA
18.28%
Profit Margin
22.40%
Op Margin
27.01%
EPS (Latest Qtr)
₹185.85
EPS (TTM)
₹730.46

Balance Sheet & Liquidity

Debt/Equity
3.60
Quick Ratio
1.77
Current Ratio
2.55
Debt
₹171.99 Cr
Total Assets
₹6,501.93 Cr
Current Assets
₹3,770.69 Cr
Working Capital
₹2,294.12 Cr

Ownership

Promoter Holding
75.55%
Chg in Prom Hold
-
FII / Inst Holding
7.85%
Chg in FII Hold
0.06%

Financial Snapshot

Enterprise Value
₹54,852.58 Cr
Total Revenue (TTM)
₹6,929.05 Cr
EBITDA
₹1,892.08 Cr
Free Cash Flow
₹1,373.31 Cr
Operating Cash Flow
₹1,319.24 Cr
Shares Outstanding
₹2.12 Cr
Gross Margin
46.71%
Payout Ratio
65.04%

Growth (CAGR)

Revenue 5Y
9.03%
Profit 5Y
17.80%
Revenue (YoY)
6.50%
Earnings (YoY)
7.60%

PROS

  • Strong return on equity of 34.5%.
  • Healthy ROCE of 41.9%.
  • Excellent profit margin of 22.4%.
  • Profit CAGR of 17.8% over 5 years.
  • Generates positive free cash flow.

CONS

  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ABBOTINDIA Abbott India Limited NIFTY_MIDNSEPHARMA 26,855.00 36.76 ₹57,065.00 Cr 1.95% 41.87% 34.46% 9.03% 17.80%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,799.20 37.59 ₹4.32 L Cr 0.92% 17.94% 14.72% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 6,667.00 68.97 ₹1.77 L Cr 0.45% 18.96% 16.19% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,410.80 68.96 ₹1.49 L Cr 0.86% 9.06% 16.98% 13.27% 20.21%
5 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,401.00 29.16 ₹1.13 L Cr 0.93% 14.88% 11.74% 7.23% 11.45%
6 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,303.50 25.90 ₹1.09 L Cr 0.61% 14.00% 11.83% 10.96% -2.35%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,077.70 21.51 ₹1.08 L Cr 0.09% 19.24% 18.32% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,267.70 19.49 ₹1.04 L Cr 0.53% 28.42% 26.91% 19.10% 131.46%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,375.60 51.29 ₹98,090.71 Cr 0.08% 13.78% 12.45% 17.73% 14.28%
⚙Ad space

Quarterly Results

Figures in INR.

Metric Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 1,604.59 Cr1,738.35 Cr1,757.15 Cr1,724.04 Cr1,709.51 Cr
Cost of Revenue 855.96 Cr942.12 Cr936.85 Cr908.81 Cr905.04 Cr
Gross Profit 748.63 Cr796.23 Cr820.30 Cr815.23 Cr804.47 Cr
Operating Expenses 338.02 Cr370.12 Cr336.77 Cr370.53 Cr342.69 Cr
Operating Income 410.61 Cr426.11 Cr483.53 Cr444.70 Cr461.78 Cr
EBITDA 504.56 Cr518.43 Cr572.12 Cr533.23 Cr556.44 Cr
Interest Expense 3.92 Cr5.82 Cr7.55 Cr5.48 Cr6.14 Cr
Pretax Income 482.71 Cr493.13 Cr545.93 Cr508.98 Cr531.23 Cr
Tax Provision 115.67 Cr127.27 Cr130.66 Cr133.02 Cr136.30 Cr
Net Income 367.04 Cr365.86 Cr415.27 Cr375.96 Cr394.93 Cr
Diluted EPS 172.72172.17195.42176.92185.85

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -5,346.73 Cr5,847.19 Cr6,409.15 Cr6,929.05 Cr
Cost of Revenue -2,983.97 Cr3,232.35 Cr3,496.78 Cr3,692.82 Cr
Gross Profit -2,362.76 Cr2,614.84 Cr2,912.37 Cr3,236.23 Cr
Operating Expenses -1,215.49 Cr1,209.30 Cr1,289.57 Cr1,420.11 Cr
Operating Income -1,147.27 Cr1,405.54 Cr1,622.80 Cr1,816.12 Cr
EBITDA -1,359.78 Cr1,701.37 Cr1,970.18 Cr2,180.22 Cr
Interest Expense -15.99 Cr12.45 Cr11.43 Cr24.99 Cr
Pretax Income -1,273.82 Cr1,617.75 Cr1,886.95 Cr2,079.27 Cr
Tax Provision -324.41 Cr416.53 Cr472.51 Cr527.25 Cr
Net Income -949.41 Cr1,201.22 Cr1,414.44 Cr1,552.02 Cr
Diluted EPS -446.78565.28665.62730.36

Compounded Sales Growth

5 Years:9.03%
1 Year:6.50%

Compounded Profit Growth

5 Years:17.80%
1 Year:7.60%

Stock Price Performance

1 Year:-10.28%
6 Months:-11.09%
3 Months:+1.86%
1 Month:+5.58%

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -4,555.51 Cr5,193.49 Cr5,917.31 Cr6,501.93 Cr
Current Assets -3,025.11 Cr3,245.84 Cr4,765.11 Cr3,770.69 Cr
Cash & Equivalents -239.67 Cr291.74 Cr560.59 Cr442.33 Cr
Inventory -648.85 Cr619.58 Cr882.04 Cr947.26 Cr
Receivables -318.80 Cr319.11 Cr380.23 Cr361.73 Cr
Total Liabilities -1,366.97 Cr1,494.60 Cr1,684.16 Cr1,727.74 Cr
Current Liabilities -1,206.02 Cr1,342.72 Cr1,407.19 Cr1,476.57 Cr
Long Term Debt -----
Total Debt -113.17 Cr83.23 Cr196.67 Cr171.99 Cr
Total Equity -3,188.54 Cr3,698.89 Cr4,233.15 Cr4,774.19 Cr
Shares Outstanding -2.12 Cr2.12 Cr2.12 Cr2.12 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -893.39 Cr1,212.81 Cr1,011.84 Cr1,319.24 Cr
Investing Cash Flow --147.71 Cr-416.03 Cr182.18 Cr-371.38 Cr
Financing Cash Flow --638.72 Cr-744.71 Cr-925.17 Cr-1,066.12 Cr
Capital Expenditure --34.11 Cr-48.33 Cr-52.60 Cr-40.92 Cr
Free Cash Flow -859.28 Cr1,164.48 Cr959.24 Cr1,278.32 Cr
Net Change in Cash -106.96 Cr52.07 Cr268.85 Cr-118.26 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -44.2%44.7%45.4%46.7%
Operating Margin % -21.5%24.0%25.3%26.2%
Net Margin % -17.8%20.5%22.1%22.4%
ROE % -29.8%32.5%33.4%32.5%
ROCE % -34.3%36.5%36.0%36.1%

Shareholding Pattern

Insiders
75.55%
Institutions
7.85%
Public Float
32.10%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ABBOTINDIA

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space